These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15049387)

  • 21. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
    Cohen A; Bregman B; Agabiti Rosei E; Williams B; Dubourg O; Clairefond P; Brudi P; Gosse P; Guéret P
    J Hum Hypertens; 1998 Jul; 12(7):479-83. PubMed ID: 9702935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy.
    Müller-Brunotte R; Edner M; Malmqvist K; Kahan T
    J Hypertens; 2005 Mar; 23(3):633-40. PubMed ID: 15716707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
    Thürmann PA; Kenedi P; Schmidt A; Harder S; Rietbrock N
    Circulation; 1998 Nov; 98(19):2037-42. PubMed ID: 9808602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
    Kurland L; Melhus H; Karlsson J; Kahan T; Malmqvist K; Ohman KP; Nyström F; Hägg A; Lind L;
    J Hypertens; 2001 Oct; 19(10):1783-7. PubMed ID: 11593098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project.
    Schneider MP; Klingbeil AU; Delles C; Ludwig M; Kolloch RE; Krekler M; Stumpe KO; Schmieder RE
    Hypertension; 2004 Jul; 44(1):61-6. PubMed ID: 15184349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
    von zur Mühlen B; Kahan T; Hägg A; Millgård J; Lind L
    J Hypertens; 2001 Oct; 19(10):1813-8. PubMed ID: 11593101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension.
    Karlsson J; Lind L; Hallberg P; Michaëlsson K; Kurland L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    Clin Cardiol; 2004 Jun; 27(6):347-50. PubMed ID: 15237695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
    Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
    J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
    Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
    Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol.
    Makris TK; Stavroulakis GA; Krespi PG; Hatzizacharias AN; Triposkiadis FK; Tsoukala CG; Votteas VV; Kyriakidis MK
    Am J Hypertens; 2000 Jul; 13(7):783-8. PubMed ID: 10933570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension.
    Stumpe KO; Haworth D; Hoglund C; Kerwin L; Martin A; Simon T; Masson C; Kassler-Taub K; Osbakken M
    Blood Press; 1998 Jan; 7(1):31-7. PubMed ID: 9551875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
    Schiffrin EL
    Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study.
    Jekell A; Malmqvist K; Wallén NH; Mörtsell D; Kahan T
    J Cardiovasc Pharmacol; 2013 Dec; 62(6):559-66. PubMed ID: 24084214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
    Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Losartan and the LIFE-study. Antihypertensive treatment with AT1-receptor antagonist].
    Kjeldsen SE; Omvik P
    Tidsskr Nor Laegeforen; 1996 Feb; 116(4):504-7. PubMed ID: 8644056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
    Ambrose J; Pribnow DG; Giraud GD; Perkins KD; Muldoon L; Greenberg BH
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):433-9. PubMed ID: 10069680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.
    Mitsunami K; Inoue S; Maeda K; Endoh S; Takahashi M; Okada M; Sugihara H; Kinoshita M
    Cardiovasc Drugs Ther; 1998 Oct; 12(5):469-74. PubMed ID: 9926278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
    Thürmann PA
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S33-6; discussion S41-3. PubMed ID: 10028952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.
    Gaudio C; Ferri FM; Giovannini M; Pannarale G; Puddu PE; Vittore A; Fera MS; Vizza CD; Fedele F
    J Cardiovasc Pharmacol; 2003 Nov; 42(5):622-8. PubMed ID: 14576510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.